Rajesh Gacche

Prof. Dr. Rajesh Gacche


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2023 in Drug Discovery Today
Verified
Journal Article
Closed access
MPManasi S. Pote
Manasi S. Pote
RGRajesh Gacche
Rajesh Gacche

1 August 2014 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
RGRajesh Gacche
Rajesh Gacche
RMRohan J. Meshram
Rohan J. Meshram

3 July 2022 in Drug Resistance Updates
Verified
Journal Article
Closed access
DSDeepshikha Singh
Deepshikha Singh
YAYehuda G. Assaraf
Yehuda G. Assaraf
RGRajesh Gacche
Rajesh Gacche

1 January 2018 in Drug Resistance Updates
Verified
Journal Article
Closed access
RGRajesh Gacche
Rajesh Gacche
YAYehuda G. Assaraf
Yehuda G. Assaraf

1 June 2015 in Oncogenesis
Verified
Journal Article
Open access
PDF file
RGRajesh Gacche
Rajesh Gacche
Since the establishment of tumor angiogenesis as a therapeutic target, an excitement in developing the anti-angiogenic agents was resulted in tailoring a humanized monoclonal antibody (Bevacizumab) against vascular endothelial growth factor (VEGF): a key factor in recruiting angiogenesis. The past three decades’ research in the area of angiogenesis also invented a series of novel and effective anti-angiogenic agents targeting the VEGF signaling axis. Despite the demonstrable clinical benefits of anti-angiogenic therapy, the preclinical and clinical data of the current therapeutic settings clearly indicate the transient efficacy, restoration of tumor progression and aggressive recurrence of tumor invasion after the withdrawal of anti-angiogenic therapy. Therefore, the impact of this therapeutic regime on improving overall survival of patients has been disappointing in clinic. The recent advances in pathophysiology of tumor angiogenesis and related molecular and cellular underpinnings attributed the conspiracy of compensatory angiogenic pathways in conferring evasive and intrinsic tumor resistance to anti-angiogenic agents. The understandings of how these pathways functionally cross-talk for sustaining tumor angiogenesis during VEGF blockade is essential and perhaps may act as a basic prerequisite for designing novel therapeutic strategies to combat the growing arrogance of tumors toward anti-angiogenic agents. The present review offers a discourse on major compensatory angiogenic pathways operating at cellular and molecular levels and their attributes with resistance to anti-angiogenic agents along with strategic opinions on future setting in targeting tumor angiogenesis.

1 November 2013 in Progress in Biophysics and Molecular Biology
Verified
Journal Article
Closed access
RGRajesh Gacche
Rajesh Gacche
RMRohan J. Meshram
Rohan J. Meshram